Jim. Thanks,
now on shares and independent exchange exchange fully company focused portfolio with process. was in by thrilled in support start productivity We much strategy. innovation, Let me Elanco and Elanco company execution Xx Lilly demand oversubscribed. which in appreciate saying how offer the for mode is nearly the and interest our a we through the your our were
X. Slide Let’s on the highlights begin with
show across QX is Our improving. Profitability the board. execution results
products new are growing. Our
our and foundation we a fit-for-purpose We’ve business are in Elanco. We’re pipeline markets. independent for augmented more launching the building presentations with more development investments
manufacturing animal show again of I to that the the prior strength is which quarter seen in the which a will are rationalize like our In operation in the contract and taken I our line for margin, results industry. and to expectations. our quarters, and manufacturing key past in underlying our we’ve summary, fundamentals. begin name our more the details margin is demonstrate would lean our provide our expansion categories implement important with variability sales element business SKUs, Our reduce health with a many across across It in gross the sales infrastructure, consolidate to years suppliers moment, techniques actions in productivity common trends a understand to We’ve few. several agenda. over which of and is
to now income the see in start You benefit these can actions our statement. of
in to point income. adjusted XXX improvement pleased The growth improvement We accelerated drives basis XX.X%. margin the quarter this are margin with gross in our
adjusted the our before example, XX% and taxes, interest, depreciation grew earnings quarter. For amortization in
new in Our made our expand These VetDC. and last new innovation agreement to commercial pillars and of actions as and advance have and launched three and The XX% Aratana of week, our of also XX% additional newly portfolio grew announced we strategy. important acquire a with productivity And, to investments intent with we all our strategic portfolio products offer presentations. sales continue geographies we products well. now total perform XX continue represents to
enabled $X.XX for execution deliver quarter. share per adjusted of earnings to the Our us
closer Slide sales take look at performance a Now let’s on our X.
in guidance swine for Taking goals. quarterly here is My A at slightly especially the our variability our more portfolio our reinforce this think are our the we key African sales To key the swine are representative results is headwind. quarter it’s message year, quarter. tracking provides into fever, particularly are context. of despite during full approach, confidence put to call. is a will will This to is variable our business more we fundamentals constant we apparent the of you important strong trajectory. that which our address I sales a assessment African and The we view currency in longer maintaining see believe fever what performance that of our
window. the For view example, this pattern constant fluctuations XX% rate for Disease while Companion that quarter, anomalies with Overall, Animal The normalizes at we talk in common track. things Therapeutics in leading the Likewise, longer-term quarter. and Prevention XX% declined our months quarter the about this XX% X% six vet are in over consistent and this more is growth trajectory. the given of at rates. Companion are later call. Animal sales specific growth with will on impact pleased This six-month are impacting longer indicators this the are purchasing performance business demand the is exchange clinic QX often and Todd
fever that This sales worsened has spreading Now due disease analysts since are fluid situation a Herd markets. situation swine is with We QX nations. $X impact African to is regarding other epidemic. the Asian and XX% approximately African impacted quarter significant some the call, industry China to X% global million. total reduction citing fever, protein or in losses XX% our swine estimate the the that in to first will our
a term. increased supply production not we global production mitigate may beef increased in offset gap, While the and from and the other swine full projecting are markets poultry near
underlying the and process Importantly, and the beef poultry well for production demand swine, globally. persists. longer-term a in lesser bodes the This to China extent protein recovery for prospects for
total spread to customers as Roughly We come will work support X% contain of the from China. to monitor company rebuild continue we’ll disease situation sales our herds. and the and of the our they
African by year. fever that approximately impact international XX million to may for is sales estimate million XX current swine our Our full the
our to Our elsewhere intent is this portfolio. offset in headwind
the earnings keep pillars of and to X our will across three the we investors our since evolving situation business. call We of strategy. Slide summarizes headwind apprised events our see the this of some main last
since I XXXX QX XX% over innovation million as to portfolio front, grew in XXXX innovation XX the On mentioned, revenue. launched of our
You the products on Slide can growth of see trajectory these XX.
We continue the the launching reach strong Galliprant We new dogs our EU EU. across in launched seeing for geographies. and products signals demand are expand in to by these
received we as U.S. as well markets for Additionally, of in smaller approval several the other outside Brazil Correlink
for line proportion core constant of sales, exchange. we On an of the continue XXX million top million, also these overall to foreign the the X% revenue, Exits growing revenue exits, portfolio, of a X% Strategic increase delivered and exchange in when business decline excluding as impact rates. excluding at accounted XXX our of
quarter sales. from All Prevention, XX% nearly of Health April. early have QX represent been our Galliprant & Future Our and cleared Companion Therapeutics targeted grew of XXXX Animal categories; backorders growth Protein Animal Disease in Companion the X% as and
Galliprant batches bulk year in In fact, the XXXX, quarter the entire we’ve than already in manufactured XXXX. did we of of first more of
We a continue a have to now the full launching in our and suite we presentations quarter. expand full in have after now available Credelio. the for new offerings EU cats available dogs for the U.S. suite In market we for
in companion launched campaign growth. This to for a television of direct-to-consumer approach awareness digital brands. a Elanco April, Credelio number complements for multichannel animal Finally, drive our and continued
the the bolus value are aggressively for of QX. in products innovative expected and QX We to these investing maximize
I and margin of manufacturing in the work capacity productivity. process manufacturing In sites. pillar, for from third time. been product, doing expansion the The margin efforts reduction has our our for we organization goals. support platform discussed the our some to turning improvements Now driving of the and in of several gross completed in-sourcing long-term Cheristin chewie internal QX, utilization our our cost better continue
site And for of a new reduction API pharmaceutical source we to Credelio. will which a begin we’ll in XXXX API the in active Additionally, new meaningful over costs. to ingredient result course of established the future transition
which a to produce and enhanced our manufacturing consistently the improvements technical of costs reducing several our Finally, we’ve poultry vaccines. products more completed ability vaccine while number manufacturing in for have process, reliable
go-to-market meaningful On to markets is on the last are in countries countries. We’ve we’re decision to of complete services benefit. various announced number commercial with Overall, we agenda the to in delivering agreements now partners in productivity executing continues a December. the and financial and progress established XX XX model SG&A our side, provide change
turn to the color to results provide guidance and our financial Todd I’ll Now more for QX call over on XXXX.
